Literature DB >> 10817741

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.

S Maesaki1, M A Hossain, Y Miyazaki, K Tomono, T Tashiro, S Kohno.   

Abstract

The efficacy of FK463, a new (1,3)-beta-D-glucan synthase inhibitor, against azole-resistant Candida albicans strains has been studied. The MIC of FK463 was lower than those of azoles and amphotericin B against CDR1-expressing C26 and CaMDR-expressing C40 strains. All mice treated with FK463 (1 mg/kg) survived disseminated murine candidiasis. The fungal burden in the kidney after 6 days was markedly reduced after therapy with FK463 and amphotericin B sodium deoxycholate, and plasma (1,3)-beta-D-glucan concentration was found to be lower in FK463-treated mice. In our study, FK463 was found to be a potent antifungal agent against disseminated infection with azole-resistant C. albicans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817741      PMCID: PMC89945          DOI: 10.1128/AAC.44.6.1728-1730.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

Authors:  D Sanglard; F Ischer; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 2.  Molecular mechanisms of drug resistance in fungi.

Authors:  H Vanden Bossche; P Marichal; F C Odds
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

3.  The emerging fungal threat.

Authors:  S Sternberg
Journal:  Science       Date:  1994-12-09       Impact factor: 47.728

4.  Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains.

Authors:  S Maesaki; P Marichal; M A Hossain; D Sanglard; H Vanden Bossche; S Kohno
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

5.  Comparison between Wako-WB003 and Fungitec G tests for detection of (1-->3)-beta-D-glucan in systemic mycosis.

Authors:  M A Hossain; T Miyazaki; K Mitsutake; H Kakeya; Y Yamamoto; K Yanagihara; S Kawamura; T Otsubo; Y Hirakata; T Tashiro; S Kohno
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

6.  Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance.

Authors:  G D Albertson; M Niimi; R D Cannon; H F Jenkinson
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  High prevalence of antifungal resistance in Candida spp. from patients with AIDS.

Authors:  D Law; C B Moore; H M Wardle; L A Ganguli; M G Keaney; D W Denning
Journal:  J Antimicrob Chemother       Date:  1994-11       Impact factor: 5.790

8.  Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis.

Authors:  T Miyazaki; S Kohno; K Mitsutake; S Maesaki; K Tanaka; N Ishikawa; K Hara
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

9.  Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes.

Authors:  T Obayashi; M Yoshida; T Mori; H Goto; A Yasuoka; H Iwasaki; H Teshima; S Kohno; A Horiuchi; A Ito
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

10.  Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.

Authors:  M B Kurtz; E M Bernard; F F Edwards; J A Marrinan; J Dropinski; C M Douglas; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  16 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; J Lowther; A Bryskier; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis.

Authors:  N Undre; P Stevenson; E Baraldi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-09-29       Impact factor: 2.441

4.  Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.

Authors:  J Keirns; T Sawamoto; M Holum; D Buell; W Wisemandle; A Alak
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

5.  Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents.

Authors:  Christopher F Hoehamer; Edwin D Cummings; George M Hilliard; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

6.  Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

Authors:  S A Messer; D J Diekema; L Boyken; S Tendolkar; R J Hollis; M A Pfaller
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

Review 7.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.

Authors:  Sevtap Arikan; Pinar Yurdakul; Gulsen Hascelik
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  In vitro antifungal activity of micafungin and caspofungin against dermatophytes isolated from China.

Authors:  Ying-qiu Bao; Zhe Wan; Ruo-yu Li
Journal:  Mycopathologia       Date:  2012-09-17       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.